JB Pharma Q3 Profit Jumps 22% on Strong Domestic, International Growth

• JB Chemicals and Pharmaceuticals reported a net profit of ₹162.5 crore in Q3 FY26, a 21.6% increase year-on-year.
• Revenue grew 14.1% to ₹963.5 crore, driven by broad-based growth in both domestic and international segments.
• Operating margin expanded to 27.8% due to better cost control, favorable product mix, and operational efficiencies.
• Domestic formulations business grew 10% to ₹620 crore, outperforming the Indian Pharmaceutical Market (IPM) with 12% growth versus IPM's 9%.
• International business revenue rose 12% to ₹445 crore, supported by strong performance in international formulations and CDMO business.

Why It Matters: JB Pharma's Q3 FY26 profit surged 22% due to robust domestic and international business expansion.